Phase Ib Study of CBP-1019 in Combination With FOLFOX +/- Bevacizumab, Pembrolizumab, or Enzalutamide for Metastatic TRPV6-overexpressing Solid Tumors of Epithelial Origin
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
CStone Pharmaceuticals
Astellas Pharma Inc
Genmab
Mirati Therapeutics Inc.
Nanjing Leads Biolabs Co.,Ltd
Akeso
Merck Sharp & Dohme LLC
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
EMD Serono
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Qilu Pharmaceutical Co., Ltd.
BeiGene
Providence Health & Services
UCB Pharma
Shanghai Junshi Bioscience Co., Ltd.
Helsinki University Central Hospital
Gilead Sciences
AstraZeneca
University of Nebraska
AstraZeneca
Tianjin Medical University Cancer Institute and Hospital
Hoffmann-La Roche
National Cancer Centre, Singapore
Shanghai JMT-Bio Inc.
Lumos Pharma
Eli Lilly and Company
Dana-Farber Cancer Institute
ASLAN Pharmaceuticals
SuZhou Stainwei Biotech Inc.
UNC Lineberger Comprehensive Cancer Center
Ziekenhuis Oost-Limburg
SCRI Development Innovations, LLC
PharmaEngine
National Institutes of Health Clinical Center (CC)
Valerio Therapeutics
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Northwestern University
Mayo Clinic
AstraZeneca